|
Real-time
Boerse Muenchen
15:14:23 2026-08-27 EDT
|
5-day change | 1st Jan Change | ||
| 0.3620 EUR | 0.00% |
|
0.00% | +21.68% |
| 02:40am | The FDA will issue its decision on Nicox's NCX 470 by the end of next April |  |
| 02:03am | US FDA to Complete Nicox's Glaucoma Drug Review by April 2027 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 378B | |||||
| 70.23B | |||||
| 12.15B | |||||
| 8.45B | |||||
| 5.17B |
- Stock Market
- Stocks
- ALCOX Stock
- NXOA Stock
- Charts Nicox SA
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
